Bristol-Myers Squibb Company Ce
CELG-RI · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $48,300,000 | $45,006,000 | $46,159,000 | $46,385,000 |
| % Growth | 7.3% | -2.5% | -0.5% | – |
| Cost of Goods Sold | $20,868,000 | $10,693,000 | $10,137,000 | $9,940,000 |
| Gross Profit | $27,432,000 | $34,313,000 | $36,022,000 | $36,445,000 |
| % Margin | 56.8% | 76.2% | 78% | 78.6% |
| R&D Expenses | $11,159,000 | $9,299,000 | $9,509,000 | $10,195,000 |
| G&A Expenses | $6,365,000 | $0 | $0 | $0 |
| SG&A Expenses | $7,865,000 | $7,772,000 | $7,814,000 | $7,690,000 |
| Sales & Mktg Exp. | $1,500,000 | $0 | $7,814,000 | $7,690,000 |
| Other Operating Expenses | -$1,250,000 | $9,047,000 | $9,595,000 | $10,023,000 |
| Operating Expenses | $17,774,000 | $26,118,000 | $26,918,000 | $27,908,000 |
| Operating Income | $9,658,000 | $8,195,000 | $9,104,000 | $8,537,000 |
| % Margin | 20% | 18.2% | 19.7% | 18.4% |
| Other Income/Exp. Net | -$18,037,000 | $245,000 | -$1,391,000 | -$439,000 |
| Pre-Tax Income | -$8,379,000 | $8,440,000 | $7,713,000 | $8,098,000 |
| Tax Expense | $554,000 | $400,000 | $1,368,000 | $1,084,000 |
| Net Income | -$8,948,000 | $8,025,000 | $6,327,000 | $6,994,000 |
| % Margin | -18.5% | 17.8% | 13.7% | 15.1% |
| EPS | -4.41 | 3.88 | 2.97 | 3.15 |
| % Growth | -213.7% | 30.6% | -5.7% | – |
| EPS Diluted | -4.41 | 3.86 | 2.95 | 3.12 |
| Weighted Avg Shares Out | 2,027,000 | 2,069,000 | 2,130,000 | 2,221,000 |
| Weighted Avg Shares Out Dil | 2,027,000 | 2,078,000 | 2,146,000 | 2,245,000 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1,947,000 | $1,166,000 | $1,232,000 | $1,334,000 |
| Depreciation & Amortization | $9,600,000 | $9,760,000 | $10,276,000 | $10,686,000 |
| EBITDA | $3,168,000 | $19,366,000 | $19,221,000 | $20,118,000 |
| % Margin | 6.6% | 43% | 41.6% | 43.4% |